- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04103203
Fast Assay for Pathogen Identification - Quasi-Experimental Intervention Study (FAPIC-QE)
October 16, 2020 updated by: prof. dr. Inge Gyssens, Hasselt University
The performance and clinical impact of two diagnostic systems will be evaluated using whole blood samples that are collected in parallel with samples for blood culture.
As the rapid diagnostic systems will have the largest impact on severely ill patients (in need of a fast diagnosis) with bacterial infection, the evaluation will be performed in patients suspected of bacteraemia.
During the study the new systems will be used in parallel with routine blood cultures.
In alternating periods of 1 month, the results of the diagnostic system will be communicated to treating physicians (intervention) or not revealed (control).
Blood culture results will be reported throughout the complete study period.
Patients with suspected sepsis at the Emergency Department (ED), the department of infectious diseases/nephrology, and the department of haemodialysis will be included.
In routine care, two blood culture sets (2x2 bottles) per patient are collected.
One extra blood sample (EDTA tube, 9 ml of blood) will be sampled for each routine set of blood cultures.
In addition, the clinical data of the patients will be collected.
The samples will be sent to the clinical laboratory where samples are tested with the new systems during regular working hours in batches of 8 samples per run (2-3 runs per day).
On average, 10%-20% of the blood cultures drawn on the presumption of bacteraemia yield bacterial pathogens.
Previous data show that 13% of patients yield positive blood cultures.
Thus, in order to collect blood samples of 100 new episodes of bacteraemia approximately 1000 patients (2000 blood cultures + 1000 EDTA tubes) have to be collected for each system (2000 patients in total).
The results of the systems will be used to evaluate the clinical utility of the system regarding time to antibiotic treatment change and bacteraemia management.
The system will be used directly for the diagnosis of patients, resulting in a possible change of treatment strategy.
However, routine blood culture practices will still be done during the whole study period.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1978
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Limburg
-
Hasselt, Limburg, Belgium, 3500
- Jessa Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Suspicion of sepsis
- The drawning of blood cultures
- Age >18 years
Exclusion Criteria:
- Children (<18 years)
- Patients who are not hospitalized and sent home after ED admission
- Duplicate blood cultures from the same bacteraemia episode (7days between positives with the same organism, or 24h for different organisms)
- Patients from who blood cultures are drawn on Friday evening (17h) or Saturday during intervention periods
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: New diagnostic results NOT available
Patients with suspected sepsis are included.
Blood samples will be collected and analysed with the new diagnostics.
However, results will not be communicated.
Only the results of routine blood cultures will be availabtle to the treating physician.
No intervention will take place, care is provided according to normal routine practices.
|
|
Experimental: New diagnostic results available
Patients with suspected sepsis are included.
Blood samples will be collected and analysed with the new diagnostics.
Results will be communicated via telephone by the consultant microbiologist and the electronic medical file to the treating physician.
Results of routine blood cultures will also be available for all patients.
Results of the new diagnostics are expected earlier, and the treating physician is able to make an earlier decision in terms of antibiotic therapy if he/she deems it necessary.
|
Test results of the new diagnostics will be available to the treating physician.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median time from specimen collection/arrival in the laboratory until antibiotic regimen change
Time Frame: at study completion, 10 months
|
Time period between collection of blood cultures until the first change in antibiotic regimen
|
at study completion, 10 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median time to appropriate, species-specific antibiotic therapy
Time Frame: at study completion, 10 months
|
Time period between collection of blood cultures until the first administration of species-specific antibiotic therapy
|
at study completion, 10 months
|
In-hospital mortality
Time Frame: at study completion, 10 months
|
In-hospital mortality
|
at study completion, 10 months
|
Time to organism identification
Time Frame: at study completion, 10 months
|
Time period between collection of blood cultures until the time to identification of a causative organism with the new diagnostics and with blood cultures
|
at study completion, 10 months
|
Time to effective therapy
Time Frame: at study completion, 10 months
|
Time period between collection of blood cultures until the first administration of antibiotic therapy effective againts the causative organism
|
at study completion, 10 months
|
Time to optimal therapy
Time Frame: at study completion, 10 months
|
Time period between collection of blood cultures until the first administration of antibiotic therapy that is optimal for patient recovery
|
at study completion, 10 months
|
30-day all cause mortality
Time Frame: at study completion, 10 months
|
Number of patients with 30-day all cause mortality
|
at study completion, 10 months
|
Length-of-stay
Time Frame: at study completion, 10 months
|
Length of hospital stay
|
at study completion, 10 months
|
Length of ICU stay
Time Frame: at study completion, 10 months
|
Length of stay in an Intensive Care Unit
|
at study completion, 10 months
|
Destination at Discharge
Time Frame: at study completion, 10 months
|
Destination after discharge (home, rehabilitation home, nursing home, ...)
|
at study completion, 10 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Inge C Gyssens, MD, PhD, Hasselt University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.
- Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377. doi: 10.1007/s00134-017-4683-6. Epub 2017 Jan 18.
- Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD, Singer M; Sepsis Definitions Task Force. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):775-87. doi: 10.1001/jama.2016.0289.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2019
Primary Completion (Actual)
April 30, 2020
Study Completion (Actual)
April 30, 2020
Study Registration Dates
First Submitted
July 12, 2019
First Submitted That Met QC Criteria
September 24, 2019
First Posted (Actual)
September 25, 2019
Study Record Updates
Last Update Posted (Actual)
October 19, 2020
Last Update Submitted That Met QC Criteria
October 16, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19.51/Infect.19.02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
-
Inverness Medical InnovationsCompletedSepsis | Systemic Inflammatory Response Syndrome | Severe Sepsis | Sepsis SyndromeUnited States
Clinical Trials on PathoRobot/ Patho-Doc Test result
-
University of California, Los AngelesCompletedCOVID-19United States
-
University of AarhusUnknown
-
Seoul National University Bundang HospitalCompletedGastric Cancer | Genetic PredispositionKorea, Republic of
-
Universidad Miguel Hernandez de ElcheFundación para el Fomento de la Investigación Sanitaria y Biomédica de la... and other collaboratorsUnknownProstate-Specific Antigen /BloodSpain
-
Istituto Auxologico ItalianoRecruiting
-
Brigham and Women's HospitalAgency for Healthcare Research and Quality (AHRQ)CompletedManagement of Actionable Test Results (ATRs)United States
-
Mitsubishi Tanabe Pharma CorporationCompletedPerennial Allergic RhinitisJapan
-
The University of Hong Kong-Shenzhen HospitalShenzhen Second People's Hospital; The People Hospital of Baoan Shenzhen; People... and other collaboratorsUnknown
-
Assistance Publique - Hôpitaux de ParisUnknownH Pylori Eradication | H Pylori Infection Eradication | Antibiotics Therapeutic StrategiesFrance
-
Norwegian University of Science and TechnologyUniversity of Oslo; Kathmandu University School of Medical Sciences; Universiteit...Not yet recruitingSexually Transmitted Diseases | Vaginal Discharge